Author/Authors :
Verbeke، نويسنده , , Hannelien and Struyf، نويسنده , , Sofie and Berghmans، نويسنده , , Nele and Van Coillie، نويسنده , , Els and Opdenakker، نويسنده , , Ghislain and Uyttenhove، نويسنده , , Catherine and Van Snick، نويسنده , , Jacques and Van Damme، نويسنده , , Jo، نويسنده ,
Abstract :
The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases.
